H.C. Wainwright analyst Emily Bodnar initiated coverage with a Buy rating on TransCode Therapeutics (RNAZ – Research Report) today and set a price target of $12.00. The company’s shares closed yesterday at $1.65.
Bodnar covers the Healthcare sector, focusing on stocks such as Agenus, Gracell Biotechnologies, and NovoCure. According to TipRanks, Bodnar has an average return of -7.0% and a 34.78% success rate on recommended stocks.
Currently, the analyst consensus on TransCode Therapeutics is a Moderate Buy with an average price target of $12.00.
See the top stocks recommended by analysts >>
Based on TransCode Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $4.82 million. In comparison, last year the company had a GAAP net loss of $3.47 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.
Read More on RNAZ:
- TransCode Therapeutics Reports Second Quarter 2023 Results; Provides Business Update
- Transcode Therapeutics announces results of TTX-MC138 in non-human primates
- TransCode Therapeutics Announces Positive Results in Non-human Primates with its Lead Therapeutic Candidate, TTX-MC138
- Transcode remains ‘steadfast’ on advancing pipeline, exploring collaborations
- TransCode Therapeutics CEO Letter to Shareholders
